An Exploratory Study Evaluating FDG-PET [fluorodeoxyglucose-positron emission tomography] as a Predictive Marker for mTOR [mammalian target of rapamycin] Directed Therapy With RAD 001 [everolimus] in Metastatic Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 12 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2007 New trial record.